MDGL
Madrigal Pharmaceuticals Inc
516.60$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Madrigal Pharmaceuticals Inc (MDGL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -190 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24 | -34 | -62 | -53 | 27 | -38 | -27 | -38 | -47 | -54 | -77 | -79 | -71 | -18 | -22 | -26 | -42 | -158 | -184 | -225 | -324 | -456 | -190 | |
| 1.0 | 1.5 | 2.5 | 3.7 | 3.4 | 2.7 | 2.5 | 1.9 | 1.5 | 0.7 | 0.5 | 0.7 | 0.7 | 0.0 | 0.1 | 0.1 | 0.1 | 0.5 | 0.4 | 0.5 | 0.5 | 0.7 | 4.7 | |
| – | – | – | 4.8 | 5.4 | 7.6 | 4.6 | 4.0 | 3.4 | 3.3 | 6.0 | 7.4 | 4.3 | 8.7 | 3.3 | 13 | 23 | 21 | 27 | 32 | 50 | 80 | 98 | |
| – | – | – | – | – | – | – | – | 3.4 | 3.3 | 6.0 | 7.4 | 4.3 | 7.9 | 3.3 | 13 | 23 | 21 | 27 | 32 | – | – | – | |
| 0.9 | 7.4 | 0.3 | -4.2 | 82 | 44 | -113 | -6.7 | -4.7 | 4.6 | 6.2 | -0.9 | -7.7 | -1.1 | 5.5 | -6.3 | 19 | 23 | 31 | 38 | -3.3 | -72 | -8.5 | |
| 0.8 | 1.6 | 4.9 | 1.6 | 2.4 | 2.2 | 0.5 | 0.1 | 0.7 | 0.5 | 0.8 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.2 | 0.3 | 0.2 | 0.2 | 1.5 | 1.5 | 0.5 | |
| -40 | -44 | 39 | 24 | 11 | -24 | 21 | -20 | 9.3 | -9.9 | -25 | -8.8 | 20 | 22 | -22 | -380 | 31 | 160 | -5.1 | 207 | -503 | -274 | 32 | |
| – | – | – | 1.9 | – | – | – | – | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| – | – | – | – | -0.3 | – | – | – | 28 | 0.0 | 39 | 90 | 37 | 6.0 | 174 | 314 | 0.2 | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 1.4 | -4.2 | 11 | -9.5 | -9.3 | 8.5 | – | – | 50 | 50 | 50 | 49 | 65 | 0.0 | 228 | |
| 71 | 84 | 3.8 | 39 | 44 | -1.9 | -2.1 | 45 | 37 | 116 | 69 | 85 | 40 | 14 | 174 | 314 | 0.2 | 5.1 | 171 | 313 | 595 | 735 | 256 | |
| 7.1 | 6.7 | -19 | 9.9 | 82 | -64 | -7.9 | -13 | -1.2 | 51 | -33 | -2.5 | -11 | 19 | 129 | -91 | -11 | 7.3 | -18 | 295 | -232 | 5.1 | 99 | |
| -24 | -35 | -67 | -55 | 25 | -40 | -27 | -38 | -48 | -55 | -78 | -79 | -72 | -18 | -22 | -26 | -42 | -158 | -184 | -225 | -326 | -457 | -190 |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.